Annals of Hepatology

Beyond hazard ratios: interpreting trial endpoints and survival analysis in systemic therapy for hepatocellular carcinoma Federico Piñero; Stephen L. Chan; Arndt Vogel;

Five years after IMbrave150 with clinical integration of atezolizumab plus bevacizumab in hepatocellular carcinoma Kuan-Chang Lai; San-Chi Chen;

Treatment for hepatocellular carcinoma after immunotherapy Landon L. Chan; Tsz Tung Kwong; Johnny C.W. Yau; Stephen L. Chan;